IMA Wealth Inc. Has $465,000 Stock Holdings in Guardant Health, Inc. (NASDAQ:GH)

IMA Wealth Inc. lessened its holdings in Guardant Health, Inc. (NASDAQ:GH) by 44.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,205 shares of the company’s stock after selling 13,897 shares during the period. IMA Wealth Inc.’s holdings in Guardant Health were worth $465,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. CWM LLC raised its holdings in shares of Guardant Health by 137.1% during the third quarter. CWM LLC now owns 984 shares of the company’s stock worth $29,000 after acquiring an additional 569 shares in the last quarter. BluePath Capital Management LLC acquired a new stake in Guardant Health in the third quarter valued at approximately $35,000. Headlands Technologies LLC lifted its stake in Guardant Health by 362.3% in the fourth quarter. Headlands Technologies LLC now owns 2,353 shares of the company’s stock valued at $64,000 after acquiring an additional 1,844 shares during the last quarter. Nisa Investment Advisors LLC grew its position in Guardant Health by 26.1% in the third quarter. Nisa Investment Advisors LLC now owns 3,450 shares of the company’s stock worth $102,000 after acquiring an additional 713 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC acquired a new position in shares of Guardant Health during the 3rd quarter worth $115,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Insider Buying and Selling at Guardant Health

In other news, insider Kumud Kalia acquired 2,187 shares of the firm’s stock in a transaction dated Monday, March 18th. The shares were bought at an average price of $17.82 per share, with a total value of $38,972.34. Following the acquisition, the insider now owns 12,722 shares of the company’s stock, valued at $226,706.04. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 6.20% of the company’s stock.

Analyst Upgrades and Downgrades

GH has been the subject of several analyst reports. Piper Sandler decreased their price objective on shares of Guardant Health from $40.00 to $30.00 and set an “overweight” rating for the company in a report on Monday, February 26th. Craig Hallum initiated coverage on Guardant Health in a research report on Wednesday. They issued a “buy” rating and a $28.00 price target for the company. JPMorgan Chase & Co. lowered their price objective on Guardant Health from $60.00 to $45.00 and set an “overweight” rating on the stock in a report on Friday, February 23rd. Canaccord Genuity Group reduced their target price on Guardant Health from $50.00 to $45.00 and set a “buy” rating for the company in a report on Friday, February 23rd. Finally, Guggenheim reaffirmed a “neutral” rating on shares of Guardant Health in a research report on Friday, April 5th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $39.27.

Guardant Health Stock Performance

NASDAQ:GH traded up $0.19 during trading hours on Friday, hitting $17.35. 697,962 shares of the company traded hands, compared to its average volume of 2,178,555. The company has a current ratio of 6.54, a quick ratio of 6.24 and a debt-to-equity ratio of 7.18. Guardant Health, Inc. has a twelve month low of $15.81 and a twelve month high of $41.06. The firm has a 50-day moving average of $18.74 and a 200 day moving average of $22.88. The stock has a market capitalization of $2.11 billion, a price-to-earnings ratio of -4.05 and a beta of 0.87.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Thursday, February 22nd. The company reported ($1.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.65). Guardant Health had a negative net margin of 85.02% and a negative return on equity of 301.94%. The company had revenue of $155.05 million for the quarter, compared to analyst estimates of $151.71 million. On average, analysts forecast that Guardant Health, Inc. will post -3.49 EPS for the current year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.